Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ONCODESIGN
  6. News
  7. Summary
    ALONC   FR0011766229

ONCODESIGN

(ALONC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease

11/04/2021 | 12:00pm EST

ONCODESIGN announced the strengthening of its patent portfolio concerning RIPK2 (Receptor-interacting serine/threonine-protein kinase 2) inhibitor macrocyclic compounds, as well as the successful completion of the preclinical toxicological evaluation of its ODS-101 drug candidate. The RIPK2 kinase inhibitors developed by Oncodesign have substantial therapeutic potential in inflammatory intestinal diseases aiming for a specific targeted action, a market estimated at close to USD 7 billion in 2023, an increase of +17% compared with 2018 (global figures). The medical need for an orally administered immune response regulator in inflammatory bowel disease is substantial, and complements current therapeutic options based on immunosuppressors and monoclonal antibodies.


ę S&P Capital IQ 2021
All news about ONCODESIGN
2021Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired..
CI
2021Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bo..
CI
2021ONCODESIGN : Appoints Chief Development Officer
MT
2021Oncodesign Appoints Karine Lignel as Group Chief Development Officer
CI
2021ONCODESIGN : Nomination
CO
2021ONCODESIGN : Starts R&D Deal with TiumBio for Fibrosis Drug Candidates
MT
2021Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
CI
2021Oncodesign Announces Unaudited Consolidated Sales Results for the Half Year Ended June ..
CI
2021ONCODESIGN : Half-year results
CO
2021GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
More news
Financials
Sales 2021 32,0 M 35,9 M 35,9 M
Net income 2021 1,80 M 2,02 M 2,02 M
Net Debt 2021 1,73 M 1,94 M 1,94 M
P/E ratio 2021 -31,5x
Yield 2021 -
Capitalization 65,9 M 74,4 M 74,0 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,11x
Nbr of Employees 226
Free-Float 50,6%
Chart ONCODESIGN
Duration : Period :
ONCODESIGN Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCODESIGN
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 9,65 €
Average target price 16,60 €
Spread / Average Target 72,0%
EPS Revisions
Managers and Directors
Philippe Genne Chairman & Chief Executive Officer
Arnaud Lafforgue Chief Financial & Administrative Officer
Jan Hoflack Chief Scientific Officer
Francis Bichat Director-Technology
StÚphane Gerart Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCODESIGN-4.27%74
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381